CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 16 enrolled
Drug / intervention
rosiglitazonedrug
Likely dose
rosiglitazone 2mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00614874
NCT00614874Phase 2Completed
CompareCT.gov

The Effects of the PPARy Agonist Rosiglitazone on Airway Hyperreactivity

Creighton University·interventional·Posted Feb 13, 2008·Updated Sep 2, 2011

In Brief

A Phase 2 clinical trial evaluating rosiglitazone for Asthma. Completed, enrolled 16 participants across 1 site.

Detailed Summary

Asthma is a common chronic disease characterized by airway inflammation and bronchoconstriction. This study utilizes the drug rosiglitazone (Avandia)to treat the effects of airway inflammation in patients with asthma. The study will be conducted on 14 adult steroid naive patients with asthma. Patients with qualifying pulmonary function testing values will be eligible for enrollment. Enrolled subjects will be treated with rosiglitazone orally at 2mg dose for 4 weeks. Patients will be reassessed and dosing will increase in 4 week increments up to 8mg.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAsthma
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedFeb 13, 2008
Enrollment StartDec 1, 2008
Primary CompletionFeb 1, 2010
Study CompletionMar 1, 2010
TodayJul 2, 2026
Enrollment to primary: 1.2 yearsPosted 18.4 years ago

Interventions

rosiglitazonedrug

2mg, 4mg, 8mg